Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05171647
Title A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche

non-Hodgkin lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

B-cell lymphoma


Mosunetuzumab + Polatuzumab vedotin-piiq

Mosunetuzumab + Polatuzumab vedotin-piiq + Tocilizumab

Gemcitabine + Oxaliplatin + Rituximab

Age Groups: senior | adult
Covered Countries CAN

No variant requirements are available.